iTeos soars as it inks I-O collaboration with GSK

14 June 2021
iteos_therapeutics_big

Further enhancing its immune-oncology presence, UK pharma major GlaxoSmithKline (LSE: GSK) has entered into a collaboration with Belgian biotech iTeos Therapeutics (Nasdaq: ITOS) to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody (MAb) currently in Phase I development as a potential treatment for patients with cancer.

TIGIT has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling pre-clinical data and a Phase II randomized clinical trial. News of the deal pushed iTeos’ shares up 39% to $27.82 by late-morning trading, having surged as much as 60%.

Deal could be worth more than $2 billion

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology